Country: মার্কিন যুক্তরাষ্ট্র
ভাষা: ইংরেজি
সূত্র: NLM (National Library of Medicine)
PINDOLOL (UNII: BJ4HF6IU1D) (PINDOLOL - UNII:BJ4HF6IU1D)
Novartis Pharmaceuticals Corporation
pindolol
TABLET
5 mg
ORAL
PRESCRIPTION DRUG
Visken® (pindolol) is indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic. Visken® (pindolol) is contraindicated in: 1) bronchial asthma; 2) overt cardiac failure; 3) cardiogenic shock; 4) second and third degree heart block; 5) severe bradycardia. (See WARNINGS)
White, uncoated, heart-shaped tablets; 5 mg and 10 mg, packages of 100. 5 mg tablets engraved “VISKEN 5’’ on one side, and embossed “V’’ on other side (NDC 0078-0111-05). 10 mg tablets engraved “VISKEN 10’’ on one side, and embossed “V’’ on other side (NDC 0078-0073-05). Below 86°F (30°C); tight, light-resistant container. Manufactured by: Novartis Pharmaceuticals Canada Inc. Dorval (Quebec) Canada H9R 4P5 Distributed by: Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936 REV: NOVEMBER 1998 T1999-39 89003701 2162-25-99A ©1998 Novartis
VISKEN- PINDOLOL TABLET NOVARTIS PHARMACEUTICALS CORPORATION ---------- VIS KEN T1999-39 89003701 VISKEN _ (pindolol)_ _ tablets, USP_ RX ONLY DESCRIPTION Visken (pindolol), a synthetic beta-adrenergic receptor blocking agent with intrinsic sympathomimetic activity is 1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol. Its structural formula is: Pindolol is a white to off-white odorless powder soluble in organic solvents and aqueous acids. Visken (pindolol) is intended for oral administration. _5 MG AND 10 MG TABLETS_ _Active Ingredient:_ pindolol _Inactive Ingredients:_ colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. ® ® ® ® CLINICAL PHARMACOLOGY Visken (pindolol) is a non-selective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges but does not possess quinidine- like membrane stabilizing activity. PHARMACODYNAMICS In standard pharmacologic tests in man and animals, Visken (pindolol) attenuates increases in heart rate, systolic blood pressure, and cardiac output resulting from exercise and isoproterenol administration, thus confirming its beta-blocking properties. The ISA or partial agonist activity of Visken (pindolol) is mediated directly at the adrenergic receptor sites and may be blocked by other beta-blockers. In catecholamine-depleted animal experiments, ISA is manifested as an increase in the inotropic and chronotropic activity of the myocardium. In man, ISA is manifested by a smaller reduction in the resting heart rate (4-8 beats/min) than is seen with drugs lacking ISA. There is also a smaller reduction in resting cardiac output. The clinical significance of this observation has not been evaluated and there is no evidence, or reason to believe, that exercise cardiac output is less affected by Visken (pindolol). Visken (pindolol) has been shown in controlled, double-blind clinical studies to be an effective antihypertensive agent when used as monotherapy, or when added to t সম্পূর্ণ নথি পড়ুন